Status:
COMPLETED
Mechanisms of Vasovagal Syncope
Lead Sponsor:
New York Medical College
Conditions:
Vasovagal Syncope
Postural Tachycardia Syndrome
Eligibility:
All Genders
14-29 years
Phase:
EARLY_PHASE1
Brief Summary
Vasovagal Syncope (simple postural faint) is the most common cause of acute loss of consciousness. Postural tachycardia syndrome(POTS) is the most common chronic form of postural lightheadedness. Toge...
Detailed Description
Vasovagal Syncope (VVS,simple faint) is the most common cause of transient loss of consciousness and is the acute episodic form of orthostatic intolerance(OI). Postural tachycardia syndrome (POTS) is ...
Eligibility Criteria
Inclusion
- POTS patients referred for day to day orthostatic intolerance with greater than 3 symptoms for greater than 3 months and will have the diagnosis of symptomatic postural tachycardia made during a screening tilt table test :
- dizziness
- nausea and vomiting
- palpitations
- fatigue
- headache
- exercise intolerance
- blurred vision
- abnormal sweating heat.
- Vasovagal Syncope patients will have at least 3 episodes of fainting episodes in the past year.
- Healthy control subjects
- Cases will be between the ages of 14 and 29 years old Cases will have normal physical examination, and normal electrocardiographic and echocardiographic evaluations.
- Only those free from heart disease, and from systemic illness will be eligible to participate.
- This excludes patients with illnesses and disease states known to be associated with endothelial cell dysfunction such as diabetes, renal disease, congestive heart failure, systemic hypertension, acute and chronic inflammatory diseases, neoplasm, immune mediated disease, trauma, morbid obesity and peripheral vascular disease.
- At the time of testing all patients and control subjects must refrain from vasoactive drugs for two weeks. Please check with us about any medication that you are taking.
Exclusion
- Cardiovascular causes of syncope
- An active medical condition that may explain the diagnosis
- A previous medical condition with undocumented resolution that may explain the diagnosis
- Past or present major psychiatric disorder
- Substance abuse within 2 years before onset of symptoms.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01791816
Start Date
February 1 2013
End Date
December 1 2022
Last Update
May 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Medical College/Bradhurst Building
Hawthorne, New York, United States, 10532